| Patient | Rachel Carson |
|---|---|
| Date of birth | 1907-05-27 |
| Identifiers | MRN HR-ML041-SYN-TD; SSN (made up) 000-41-5068 |
| Document date | 1960-09-08 |
| Author | Margaret Vance-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Monitoring visit at the start of the fourth ribociclib cycle. [S]
Ms. Carson is twelve weeks into letrozole and starts her fourth cycle of ribociclib today. The oncology blood tests at about day 14 of the first cycle and on schedule since have shown neutrophils between 1.3 and 1.7, with normal liver tests and electrolytes; the neutrophil count was 1.2 at her sick visit in July, without fever, and she has had no fever since. The ECG planned for about day 14 of the first cycle was not done: she was away on the coast that week for field work and the ECG was not rebooked with her blood test. It was done at the start of the second cycle, four weeks after starting: QTcF 426 ms. She has mild morning knee stiffness for about ten minutes, eased by walking, and occasional night hot flashes. She is finishing the draft of her book this month. [S]
| Element | Detail |
|---|---|
| Interval change | Cycles 1 to 3 of ribociclib completed at full dose; viral rhinosinusitis in July |
| Oncology results | Neutrophils 1.3 to 1.7; liver tests and electrolytes normal; QTcF 426 ms at the start of cycle 2 |
| Side effects | Mild knee stiffness and night hot flashes |
| Adherence | No missed doses by her diary |
| Work | Finishing the draft of her book |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Cardiovascular | Negative | No palpitations, fainting, or chest pain |
| Gastrointestinal | Negative | No nausea, diarrhea, or indigestion |
| Musculoskeletal | Positive | Morning knee stiffness for about ten minutes; no bone pain |
| Genitourinary | Negative | No vaginal bleeding |
| Integumentary | Negative | No rash; radiation skin settled |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Omeprazole 20 mg delayed-release oral capsule, one capsule by mouth once daily before breakfast, to complete eight weeks of ulcer healing | One capsule once daily before breakfast | Oral route | 1960-01-19 to 1960-04-03 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for knee pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 1959-06-02 | active | S |
| Letrozole 2.5 mg oral tablet, one tablet by mouth once daily, planned for at least five years | One tablet once daily | Oral route | 1960-06-15 | active | S |
| Ribociclib 200 mg oral tablet, two tablets (400 mg) by mouth once daily on days 1 to 21 of each 28-day cycle, with letrozole, planned for three years | Two tablets once daily on days 1 to 21 of each 28-day cycle | Oral route | 1960-06-15 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every six months for three years | One infusion every six months | Intravenous route | 1960-06-15 | active | S |
| Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1960-06-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1960-09-08 | Body height | 163 | cm | S |
| 1960-09-08 | Body weight | 59.6 | kg | S |
| 1960-09-08 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 1960-09-08 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1960-09-08 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1960-09-08 | Heart rate | 72 | /min | S |
| 1960-09-08 | Respiratory rate | 14 | /min | S |
| 1960-09-08 | Body temperature | 36.6 | Cel | S |
| 1960-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1960-09-08 | Hemoglobin [Mass/volume] in Blood | 12.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 1960-09-08 | Leukocytes [#/volume] in Blood by Automated count | 3.4 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1960-09-08 | Neutrophils [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 1.8-7.7 10*3/uL | Low | S |
| 1960-09-08 | Platelets [#/volume] in Blood by Automated count | 192 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1960-09-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.5-1.1 mg/dL | Normal | S |
| 1960-09-08 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | <=33 U/L | Normal | S |
| 1960-09-08 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | <=32 U/L | Normal | S |
| 1960-09-08 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | <=1.2 mg/dL | Normal | S |
| 1960-09-08 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1960-09-08 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.4 mg/dL | Normal | S |
| 1960-09-08 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1960-09-08 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1960-09-08 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1960-09-08; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Breasts | Left breast mildly firm after radiation; no masses. Right breast normal |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 25.5 cm on each side; knees with mild crepitus and no effusion |
| Abdomen | Soft; liver not enlarged |
| Eyes | No jaundice |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Invasive ductal carcinoma of the left breast, upper outer quadrant at 2 o'clock, 2.4 cm on imaging; core biopsy grade 2, estrogen and progesterone receptor positive, HER2 negative, Ki-67 22 percent; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern counterpart of the documented 1894 breast cancer, which was not disclosed to her | active | confirmed | C50.412 | S — Synthetic tumor details, stage, and treatment; the breast lumps, the 1960 operation, and the nondisclosure are documented (D), but no tumor details from her lifetime are used. |
| Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 80 percent) | active | confirmed | Z17.0 | S — Synthetic receptor result; no receptor status from her lifetime is known. |
| New firm lump in the upper outer quadrant of the left breast, found two weeks ago; clinically suspicious; diagnostic imaging and biopsy booked | resolved | confirmed | N63.21 | S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the lumps in the left breast in early 1960 are documented (D). |
| Duodenal ulcer found at endoscopy seven weeks ago, with Helicobacter pylori on biopsy; treated with 14 days of bismuth quadruple therapy and completing eight weeks of omeprazole; test of cure planned | resolved | confirmed | K26.9 | S — Synthetic modern ulcer; it echoes the ulcer among her documented illnesses, which the sources do not date. |
| Primary osteoarthritis of both knees, mild, with stiffness after long walks on the shore | active | confirmed | M17.0 | S — Synthetic condition; it is not linked to the documented word arthritis, which she may have used to keep her cancer private. |
| Metastatic carcinoma in two of three left axillary sentinel lymph nodes (macrometastases, no extranodal extension); pathologic stage pT2 pN1a(sn) M0, anatomic stage IIB; recurrence score 17 | active | confirmed | C77.3 | S — Synthetic surgical pathology; spread to lymph nodes is documented later in her life, but no pathology from her lifetime is used. |
| Long-term use of letrozole as adjuvant endocrine therapy, with ribociclib for three years | active | confirmed | Z79.811 | S — Synthetic treatment status. |
| Low bone mass (osteopenia) on baseline DXA before letrozole: lumbar spine T-score -1.8, femoral neck -1.3; 10-year major osteoporotic fracture risk about 7 percent (FRAX); vitamin D insufficiency | active | confirmed | M85.80 | S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor. |
| Acute viral rhinosinusitis for five days while on ribociclib, with expected grade 2 neutropenia (absolute neutrophil count 1.2) and no fever; resolved with saline irrigation | resolved | confirmed | J01.90 | S — Synthetic common illness; it echoes the sinus infection among her documented illnesses, which the sources do not date, and is not linked to that claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count on ribociclib | Every 2 weeks for 2 cycles, then at the start of the next 4 cycles | Completed today | White cells 3.4, neutrophils 1.6 (grade 1), hemoglobin 12.5, platelets 192; earlier oncology counts 1.3 to 1.7 |
| Laboratory | Liver tests on ribociclib | Every 2 weeks for 2 cycles, then at the start of the next 4 cycles | Completed today | ALT 31, AST 29, bilirubin 0.7; all earlier results normal |
| Laboratory | Electrolytes on ribociclib | At the start of each of the first 6 cycles | Completed today | Potassium 4.1, magnesium 2.0, calcium 9.5 |
| Medication safety | ECG at about day 14 of the first cycle | Day 14 of cycle 1 | Deferred | Missed, a deviation from the protocol: she was away for field work and the ECG was not booked with her blood test. It was done at the start of cycle 2 instead, QTcF 426 ms, normal, so no harm resulted. Corrective action: the oncology scheduler now books ECGs with the blood tests and confirms by telephone; any dose change or new QT-prolonging drug will prompt a repeat ECG |
| Medication safety | Interaction review | With every new medicine | Completed today | No new medicines; the July illness was treated without antibiotics |
| Medication safety | Zoledronic acid: kidney function before the next infusion | Before each infusion | Completed today | Creatinine 0.8; next infusion in December |
| Laboratory | Calcium and vitamin D adequacy | Ongoing on an aromatase inhibitor | Completed today | 25-hydroxyvitamin D 34 ng/mL on replacement |
| Examination | Aromatase inhibitor joint pain and musculoskeletal review | Every visit | Completed today | Mild morning knee stiffness, slightly longer than at baseline |
| Survey | Vasomotor and vaginal symptoms | Periodically on endocrine therapy | Completed today | Occasional night hot flashes; no treatment wanted |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | 25.5 cm on each side; no swelling |
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No signs of recurrence |
| Survey | Depression screen (PHQ-9) | At periodic intervals | Completed today | PHQ-9 3 |
| Imaging | Mammogram after breast-conserving treatment | 6 to 12 months after radiation, then yearly | Due | From late November |
| Laboratory | Routine tumor markers and body imaging | Not recommended without symptoms | Not indicated | None ordered |
| Self-management | Activity, alcohol, and work | Every visit | Completed today | Walking about 150 minutes a week; rare alcohol; writing most mornings |
Goal progress:
Guideline basis: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2024;42(18):2233-2235 (2024); KISQALI (ribociclib) tablets: prescribing information (dosage for early breast cancer; QT, hepatotoxicity, and neutropenia monitoring) (2026); Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 2022;40(7):787-800 (2022); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)
Follow-up: Oncology blood tests at the start of cycles 5 and 6. Adult preventive visit next month. Zoledronic acid in December. Mammogram from late November. Next scheduled visit 1960-10-13: adult preventive visit. [S]